{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:23:20Z","timestamp":1780496600487,"version":"3.54.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Biol"],"DOI":"10.1186\/s12915-023-01799-5","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T01:02:21Z","timestamp":1703811741000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Leveraging the predictive power of 3D organoids in dogs to develop new treatments for man and man\u2019s best friend"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2168-5809","authenticated-orcid":false,"given":"Karin","family":"Allenspach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yana","family":"Zavros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elbadawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Zdyrski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan Paul","family":"Mochel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,29]]},"reference":[{"key":"1799_CR1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nature07935","volume":"459","author":"T Sato","year":"2009","unstructured":"Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459:262\u20135.","journal-title":"Nature"},{"key":"1799_CR2","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","volume":"12","author":"D Sun","year":"2022","unstructured":"Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? Acta Pharmaceutica Sinica B. 2022;12:3049\u201362.","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"1799_CR3","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1002\/cac2.12224","volume":"41","author":"J Qu","year":"2021","unstructured":"Qu J, Kalyani FS, Liu L, Cheng T, Chen L. Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy. Cancer Commun. 2021;41:1331\u201353.","journal-title":"Cancer Commun"},{"key":"1799_CR4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41568-020-0297-3","volume":"20","author":"AK LeBlanc","year":"2020","unstructured":"LeBlanc AK, Mazcko CN. Improving human cancer therapy through the evaluation of pet dogs. Nat Rev Cancer. 2020;20:727\u201342.","journal-title":"Nat Rev Cancer"},{"key":"1799_CR5","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1158\/2767-9764.CRC-22-0468","volume":"3","author":"W Oh","year":"2023","unstructured":"Oh W, Kim AMJ, Dhawan D, Kirkham PM, Ostafe R, Franco J, et al. Development of an anti-canine PD-L1 antibody and caninized PD-L1 mouse model as translational research tools for the study of immunotherapy in humans. Cancer Res Commun. 2023;3:860\u201373.","journal-title":"Cancer Res Commun"},{"key":"1799_CR6","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.3389\/fonc.2019.01493","volume":"9","author":"DW Knapp","year":"2019","unstructured":"Knapp DW, Dhawan D, Ramos-Vara JA, Ratliff TL, Cresswell GM, Utturkar S, et al. Naturally-occurring invasive urothelial carcinoma in dogs, a unique model to drive advances in managing muscle invasive bladder cancer in humans. Front Oncol. 2019;9:1493.","journal-title":"Front Oncol"},{"key":"1799_CR7","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1111\/cas.14118","volume":"110","author":"M Elbadawy","year":"2019","unstructured":"Elbadawy M, Usui T, Mori T, Tsunedomi R, Hazama S, Nabeta R, et al. Establishment of a novel experimental model for muscle-invasive bladder cancer using a dog bladder cancer organoid culture. Cancer Sci. 2019;110:2806\u201321.","journal-title":"Cancer Sci"},{"key":"1799_CR8","doi-asserted-by":"publisher","first-page":"18051","DOI":"10.1038\/s41598-022-21706-2","volume":"12","author":"M Inglebert","year":"2022","unstructured":"Inglebert M, Dettwiler M, Hahn K, Letko A, Drogemuller C, Doench J, et al. A living biobank of canine mammary tumor organoids as a comparative model for human breast cancer. Sci Rep. 2022;12:18051.","journal-title":"Sci Rep"},{"key":"1799_CR9","doi-asserted-by":"publisher","first-page":"115079","DOI":"10.1016\/j.biopha.2023.115079","volume":"165","author":"Y Shiota","year":"2023","unstructured":"Shiota Y, Elbadawy M, Suzuki K, Tsunedomi R, Nagano H, Ishihara Y, et al. Derivation of a new model of lung adenocarcinoma using canine lung cancer organoids for translational research in pulmonary medicine. Biomed Pharmacother. 2023;165:115079.","journal-title":"Biomed Pharmacother."},{"key":"1799_CR10","doi-asserted-by":"publisher","DOI":"10.3791\/63515","author":"V Gabriel","year":"2022","unstructured":"Gabriel V, Zdyrski C, Sahoo DK, Dao K, Bourgois-Mochel A, Kopper J, et al. Standardization and maintenance of 3D canine hepatic and intestinal organoid cultures for use in biomedical research. J Vis Exp. 2022. https:\/\/doi.org\/10.3791\/63515.","journal-title":"J Vis Exp"}],"container-title":["BMC Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12915-023-01799-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12915-023-01799-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12915-023-01799-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T01:05:31Z","timestamp":1703811931000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbiol.biomedcentral.com\/articles\/10.1186\/s12915-023-01799-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,29]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1799"],"URL":"https:\/\/doi.org\/10.1186\/s12915-023-01799-5","relation":{},"ISSN":["1741-7007"],"issn-type":[{"value":"1741-7007","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,29]]},"assertion":[{"value":"5 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KA and JPM are co-founders of 3D Health Solutions, Inc., a startup entity that commercializes drug screening assays using 3D canine organoids. CZ is an employee of 3D Health Solutions, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"297"}}